Tschetter AJ, et al. - In this five-year, prospective, multicenter analysis, researchers quantified T-stage outcomes prospectively and verified historically elevated risk characteristics as they relate to results in Mohs Surgery (MS)-treated cutaneous squamous cell carcinoma (CSCC). The study sample consisted of patients undergoing MS for invasive CSCC. In this analysis, 745 tumors across 637 patients have been enlisted. Findings suggested that MS is an extremely efficient CSCC therapy and can mitigate factors that are generally deemed to be high risk. Uniform Breslow depth reporting should be taken into consideration in CSCC. The American Joint Committee on Cancer Staging Manual, 8^th edition (AJCC8-SS) and the Brigham and Women’s Hospital (BWH-SS) are helpful forecasters, but after MS they do not predict local recurrence.